A Study to Find a Suitable Dose of ASP5834 in Adults With Solid Tumors
Conditions
Solid Tumor · Non-Small-Cell Lung Cancer · Pancreatic Ductal Adenocarcinoma · Colorectal Cancer
Simple summaryAI-assisted
This summary is produced by a language model and is experimental. It may be incomplete or inaccurate and is not a substitute for professional medical advice.
Locations
UCLA Santa Monica Hematology Oncology, Santa Monica, California, United States
Winship Cancer Institute at Emory University, Atlanta, Georgia, United States
Ochsner Health, Jefferson, Louisiana, United States
START Midwest, Grand Rapids, Michigan, United States
Washington University School of Medicine, St Louis, Missouri, United States
Hackensack University Medical Center, Hackensack, New Jersey, United States
Roswell Cancer Institute, Buffalo, New York, United States
Memorial Sloan Kettering Cancer Center, New York, New York, United States
University Hospitals - UH Cleveland Medical Center, Cleveland, Ohio, United States
NEXT Oncology Dallas, Irving, Texas, United States
NEXT Oncology Virginia, Fairfax, Virginia, United States
Site FR33003, Bordeaux, New Aquitaine, France
Site FR33002, Lyon, France
Site FR33004, Pierre-Bénite, France
Site FR33001, Villejuif, France
Kansai Medical University Hospital, Hirakata, Osaka, Japan
Cancer Institute Hospital of JFCR, Koto-ku, Tokyo, Japan
Site ES34005, Barcelona, Catalonia, Spain
Site ES34001, Madrid, Spain
Site ES34003, Madrid, Spain
Study leads
Medical Lead
Study Director
Astellas Pharma Inc